Apr 09, 2026
Flow Cytometry Protocol for Human PD-L1 (CD274) Detection Using Research-Grade Anti-PD-L1 Antibodies
- QI Cheng1
- 1abinScience, AtaGenix Laboratories, Wuhan, China
External link: https://www.abinscience.com
Protocol Citation: QI Cheng 2026. Flow Cytometry Protocol for Human PD-L1 (CD274) Detection Using Research-Grade Anti-PD-L1 Antibodies. protocols.io https://dx.doi.org/10.17504/protocols.io.14egn5owyg5d/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
This protocol has been optimized and validated in our laboratory.
Created: April 09, 2026
Last Modified: April 09, 2026
Protocol Integer ID: 314751
Keywords: PD-L1, CD274, B7-H1, flow cytometry, immune checkpoint, surface staining, immuno-oncology, flow cytometry protocol for human pd, flow cytometry protocol, l1 antibodies this protocol, flow cytometry, key immune checkpoint molecule, immune checkpoint, l1 antibody, detecting pd, tumor sample, antibodies this protocol, human pd, antibody, oncology research, l1 monoclonal, cultured cell line, applicable to cultured cell line, expression on human cell, cd274, human cell, pd
Disclaimer
For research use only. Not for diagnostic or therapeutic purposes.
Abstract
This protocol describes a standard surface staining procedure for detecting PD-L1 (CD274/B7-H1) expression on human cells by flow cytometry. PD-L1 is a key immune checkpoint molecule widely studied in immuno-oncology research. This protocol has been optimized for use with abinScience research-grade anti-human PD-L1 monoclonal antibodies and is applicable to cultured cell lines, PBMCs, and dissociated tumor samples.
Guidelines
The use of human PBMCs and tumor tissue samples in this protocol requires prior approval from the users' Institutional Ethics Board (IRB) or equivalent ethics committee. Researchers must ensure compliance with all applicable institutional and national regulations governing the use of human biological materials.
Troubleshooting
Problem
Low or no signal
Solution
Antigen may be cleaved during cell harvest. Use Accutase instead of trypsin to preserve surface antigens. Also try increasing antibody concentration by titrating from 1–20 μg/mL.
Problem
High background
Solution
Insufficient Fc blocking. Increase Fc block incubation time or concentration. Also ensure paraformaldehyde fixation does not exceed 15 minutes.
Problem
Poor resolution between positive and negative populations
Solution
Always include FMO (Fluorescence Minus One) control for accurate gating. Verify that the fluorochrome choice is appropriate for your instrument laser and filter configuration.
Safety warnings
Paraformaldehyde is toxic. Handle fixation buffer in a chemical fume hood and wear appropriate PPE. Sodium azide in FACS buffer is hazardous — do not dispose down the drain.
Ethics statement
This protocol may involve human PBMCs and tumor tissue samples. Prior approval from an Institutional Ethics Board (IRB) or equivalent ethics committee is required before performing these experiments. Researchers must comply with all applicable institutional and national regulations governing the use of human biological materials.
Before start
Prepare FACS buffer, viability dye, and Fc block reagent in advance. Ensure flow cytometer is calibrated with appropriate compensation controls before acquisition.
Cell Preparation
1. Harvest cells. For adherent cells, use Accutase to avoid cleaving surface antigens. For suspension cells, collect directly.
2. Wash once with PBS, centrifuge at 300 × g for 5 minutes.
3. Resuspend cells in FACS buffer (PBS + 2% FBS + 0.05% sodium azide) at 1 × 10⁷ cells/mL.
4. Aliquot 100 μL (1 × 10⁶ cells) per well into a 96-well V-bottom plate.
Note: For tumor-derived samples, prepare a single-cell suspension using enzymatic digestion and filter through a 70 μm cell strainer before proceeding.
Viability Staining
1. Centrifuge plate at 300 × g for 5 minutes, discard supernatant.
2. Resuspend cells in 100 μL PBS containing viability dye (per manufacturer's instructions).
3. Incubate at room temperature for 15 minutes, protected from light.
4. Wash once with FACS buffer.
Fc Blocking
1. Resuspend cells in 50 μL FACS buffer containing Fc block (5 μL per test).
2. Incubate at room temperature for 10 minutes.
3. Do NOT wash. Proceed directly to antibody staining.
Primary Antibody Staining
1. Add anti-PD-L1 antibody to each well. Recommended starting concentration: 1-10 μg/mL. Titration is recommended for optimal signal-to-noise ratio.
Recommended antibodies (abinScience):
- Research Grade Atezolizumab (Cat# HV974016): https://www.abinscience.com/product/71/1388.html
- Research Grade Durvalumab (Cat# HV974026): https://www.abinscience.com/product/71/1396.html
- Research Grade Avelumab (Cat# HV974036): https://www.abinscience.com/product/71/2246.html
2. Include the following controls: unstained control, isotype control (matched host species and isotype), and FMO (Fluorescence Minus One) control.
3. Incubate on ice for 30 minutes, protected from light.
4. Wash twice with 200 μL FACS buffer, centrifuge at 300 × g for 5 minutes.
Secondary Antibody Staining (if unconjugated primary)
1. Resuspend cells in 100 μL FACS buffer containing fluorochrome-conjugated secondary antibody (e.g., AF488 anti-human IgG Fc) at the recommended dilution.
2. Incubate on ice for 20–30 minutes, protected from light.
3. Wash twice with 200 μL FACS buffer.
Note: If using a directly conjugated primary antibody, skip this step.
Fixation and Acquisition
1. Resuspend cells in 200 μL fixation buffer (2% paraformaldehyde in PBS).
2. Incubate at room temperature for 15 minutes.
3. Wash once with FACS buffer and resuspend in 200 μL FACS buffer.
4. Acquire on flow cytometer within 24 hours.
5. Collect a minimum of 10,000 events in the live cell gate for analysis.
Data Analysis and Gating Strategy
1. FSC-A vs SSC-A: gate on intact cells (exclude debris).
2. FSC-A vs FSC-H: gate on singlets.
3. Viability dye vs FSC-A: gate on live cells.
4. PD-L1 fluorescence vs FSC-A: determine PD-L1-positive population.
Report percent PD-L1-positive cells and Median Fluorescence Intensity (MFI) relative to isotype or FMO control.